NovaBay Pharmaceuticals Inc.

AMEX: NBYHealthcare / Biotechnology / USA
0.5200+0.0700+15.56%Vol 3 401 0481Y Perf -62.22%
Sep 13th, 2019 16:00
BID0.5100 ASK0.5300
Open0.4600 Previous Close0.4500
Pre-Market0.47 After-Trading0.52
 0.02 4.44%  - -%
Target Price
1.00 
Analyst Rating
— 0.00
Potencial %
92.31 
Finscreener Ranking
★★ —    -
Insiders Trans % 3/6/12M
-/-100/-100 
Value Ranking
     30.60
Insiders Value % 3/6/12M
-/-100/-100 
Growth Ranking
+     30.85
Insiders Shares Cnt. % 3/6/12M
-/-100/-100 
Income Ranking
 —    -
Market Cap (mil)13 
Earnings Rating
Buy
Price Range Ratio 52wk %
7.61 
Earnings Date
6th Aug 2019

Today's Price Range

0.44000.5800

52wk Range

0.23004.04

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Sell
Performance
1 Week
0.00%
1 Month
-31.58%
3 Months
-68.67%
6 Months
-63.64%
1 Year
-62.22%
3 Years
-83.65%
5 Years
-97.49%
10 Years
-98.86%

Name / TickerPriceChg.Chg.%
NBY0.52000.070015.56
AAPL218.75-4.3300-1.94
GOOG1 239.565.31000.43
MSFT137.32-0.2000-0.15
XOM72.640.66000.92
WFC48.920.27000.55
JNJ130.780.35000.27
FB187.19-0.2800-0.15
GE9.340.09000.97
JPM120.232.32001.97
Earnings HistoryEstimateReportedSurprise %
Q02 2019--0.14-
Q01 2019--0.24-
Q04 2018-0.14-0.0935.71
Q03 2018-0.09-0.11-22.22
Q02 2018-0.12-0.15-25.00
Q01 2018-0.07-0.14-100.00
Q04 2017-0.050.02140.00
Q03 2017-0.09-0.16-77.78
Earnings Per EndEstimateRevision %Trend
3/2019 QR-0.18-20.00Negative
6/2019 QR-0.0650.00Positive
12/2019 FY-0.2925.64Positive
12/2019 FY-0.1167.65Positive
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume3 401 048
Shares Outstanding (in ths.)25 202
Trades Count1 039
Dollar Volume630 507
Avg. Volume1 195 782
Avg. Weekly Volume1 397 009
Avg. Monthly Volume1 136 727
Avg. Quarterly Volume1 066 601
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0 (0.00 %)
Moderate Buy
0
0
0 (0.00 %)
Hold
0
0
1 (100.00 %)
Moderate Sell
0
0
0 (0.00 %)
Strong Sell
0
0
0 (0.00 %)
Rating--Hold
3.00

NovaBay Pharmaceuticals Inc.

NovaBay Pharmaceuticals Inc is a biopharmaceutical company. The company develops, manufactures, and markets anti-infective products for a multitude of uses. It is predominantly focused on commercializing prescription Avenova for the domestic eyecare market in the United States. Avenova is the only eye care product formulated with proprietary, stable and pure form of hypochlorous acid (marketed as Neutrox). NovaBay develops additional products containing Neutrox, including its NeutroPhase Skin and Wound Cleanser for wound care and CelleRx for the dermatology market. It has partnerships for NeutroPhase in the United States, as well as in other markets.

CEO: Justin M. Hall

Teplephone: +1 510 899-8800

Address: 2000 Powell Street, Emeryville 94608, CA, USA

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

0%100%

Bearish Bullish

47%53%

Bearish Bullish

43%57%

Bearish Bullish

56%44%

News